208 related articles for article (PubMed ID: 31280073)
1. A carrier-free multiplexed gene editing system applicable for suspension cells.
Ju A; Lee SW; Lee YE; Han KC; Kim JC; Shin SC; Park HJ; EunKyeong Kim E; Hong S; Jang M
Biomaterials; 2019 Oct; 217():119298. PubMed ID: 31280073
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
3. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells.
Lin Y; Wilk U; Pöhmerer J; Hörterer E; Höhn M; Luo X; Mai H; Wagner E; Lächelt U
Small; 2023 Jan; 19(2):e2205318. PubMed ID: 36399647
[TBL] [Abstract][Full Text] [Related]
4. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
Li S; Song Z; Liu C; Chen XL; Han H
ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
[TBL] [Abstract][Full Text] [Related]
5. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.
He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX
Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886
[TBL] [Abstract][Full Text] [Related]
6. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
7. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
9. Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment.
Kim SM; Shin SC; Kim EE; Kim SH; Park K; Oh SJ; Jang M
ACS Nano; 2018 Aug; 12(8):7750-7760. PubMed ID: 30028587
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
Zhen S; Lu J; Chen W; Zhao L; Li X
Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360
[TBL] [Abstract][Full Text] [Related]
11. Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy.
Wei S; Shao X; Liu Y; Xiong B; Cui P; Liu Z; Li Q
J Mater Chem B; 2022 Feb; 10(8):1291-1300. PubMed ID: 35141737
[TBL] [Abstract][Full Text] [Related]
12. Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy.
Lu Q; Chen R; Du S; Chen C; Pan Y; Luan X; Yang J; Zeng F; He B; Han X; Song Y
Biomaterials; 2022 Dec; 291():121871. PubMed ID: 36323073
[TBL] [Abstract][Full Text] [Related]
13. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.
Zhang D; Wang G; Yu X; Wei T; Farbiak L; Johnson LT; Taylor AM; Xu J; Hong Y; Zhu H; Siegwart DJ
Nat Nanotechnol; 2022 Jul; 17(7):777-787. PubMed ID: 35551240
[TBL] [Abstract][Full Text] [Related]
14. Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins.
Soares Medeiros LC; South L; Peng D; Bustamante JM; Wang W; Bunkofske M; Perumal N; Sanchez-Valdez F; Tarleton RL
mBio; 2017 Nov; 8(6):. PubMed ID: 29114029
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antiviral benefit of combination therapy with anti-HBV and anti-PD1 gRNA/cas9 produces a synergistic antiviral effect in HBV infection.
Zhen S; Qiang R; Lu J; Tuo X; Yang X; Li X
Mol Immunol; 2021 Feb; 130():7-13. PubMed ID: 33340931
[TBL] [Abstract][Full Text] [Related]
16. Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes.
Rathbone T; Ates I; Fernando L; Addlestone E; Lee CM; Richards VP; Cottle RN
CRISPR J; 2022 Jun; 5(3):397-409. PubMed ID: 35238624
[TBL] [Abstract][Full Text] [Related]
17. Cytosolic delivery of CRISPR/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein.
Qiao J; Sun W; Lin S; Jin R; Ma L; Liu Y
Chem Commun (Camb); 2019 Apr; 55(32):4707-4710. PubMed ID: 30942216
[TBL] [Abstract][Full Text] [Related]
18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
19. Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing.
Ouchi Y; Patil A; Tamura Y; Nishimasu H; Negishi A; Paul SK; Takemura N; Satoh T; Kimura Y; Kurachi M; Nureki O; Nakai K; Kiyono H; Uematsu S
Int Immunol; 2018 Apr; 30(4):141-154. PubMed ID: 29617862
[TBL] [Abstract][Full Text] [Related]
20. Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs.
Stahl EC; Sabo JK; Kang MH; Allen R; Applegate E; Kim SE; Kwon Y; Seth A; Lemus N; Salinas-Rios V; Soczek KM; Trinidad M; Vo LT; Jeans C; Wozniak A; Morris T; Kimberlin A; Foti T; Savage DF; Doudna JA
Mol Ther; 2023 Aug; 31(8):2422-2438. PubMed ID: 37403358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
